Evidence map›Paper›PMID 30616901›Full record

ArticleGynecologic oncology2019

Association of statins, aspirin, and venous thromboembolism in women with endometrial cancer.

Koji Matsuo, Marianne S Hom, Akira Yabuno, Masako Shida, Mamoru Kakuda, Sosuke Adachi, Rachel S Mandelbaum, Yutaka Ueda, Kosei Hasegawa, Takayuki Enomoto and 2 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Efficacy of Atorvastatin Against Venous Thromboembolism After Total Hip Arthroplasty.Journal of musculoskeletal & neuronal interactions · 2025
    Trial
  2. Article
  3. Article
  4. Reassessing the Risk of Venous Thromboembolism (VTE) Events in Women.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Koji MatsuoDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: koji.matsuo@med.usc.edu.
Marianne S HomDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.
Akira YabunoDepartment of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Masako ShidaDepartment of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan.
Mamoru KakudaDepartment of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.
Sosuke AdachiDepartment of Obstetrics and Gynecology, Niigata University School of Medicine, Osaka, Japan.
Rachel S MandelbaumDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.
Yutaka UedaDepartment of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Osaka, Japan.
Kosei HasegawaDepartment of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Takayuki EnomotoDepartment of Obstetrics and Gynecology, Niigata University School of Medicine, Osaka, Japan.
Mikio MikamiDepartment of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan.
Lynda D RomanDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
University of Southern California · USNiigata University · JPSaitama Medical University · JPThe University of Osaka · JPTokai University · JP

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · 1985 to 2025
$66.6M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

objectiveThe anti-thrombogenic effects of statins and aspirin have been reported in various malignancies but have not been well examined in endometrial cancer. This study examined the association between statin and/or aspirin use and venous thromboembolism (VTE) risk in endometrial cancer.

methodsThis is a multi-center retrospective study examining 2527 women with endometrial cancer between 2000 and 2015. Statin and aspirin use at diagnosis was correlated to VTE risk during follow-up on multivariable analysis.

resultsThere were 132 VTE events with a 5-year cumulative incidence rate of 6.1%. There were 392 (15.5%) statin users and 219 (8.7%) aspirin users, respectively. On multivariable analysis, statin use was associated with an approximately 60% decreased risk of VTE when compared to non-users (5-year cumulative rates 2.5% versus 6.7%, adjusted-hazard ratio [HR] 0.42, 95% confidence interval [CI] 0.19-0.92, P = 0.030) whereas aspirin did not demonstrate statistical significance (2.0% versus 6.5%, adjusted-HR 0.54, 95%CI 0.19-1.51, P = 0.24). There was a trend of joint effect between statin and aspirin although it did not demonstrate statistical significance: VTE risks for dual statin/aspirin user (adjusted-HR 0.27, 95%CI 0.04-2.07), statin alone (adjusted-HR 0.40, 95%CI 0.18-0.93), and aspirin alone (adjusted-HR 0.51, 95%CI 0.16-1.64) compared to non-use after adjusting for patient characteristics, tumor factors, treatment types, and survival events (P-interaction = 0.090). When stratified by statin type, simvastatin demonstrated the largest reduction of VTE risk (5-year cumulative rates 1.1% versus 6.7%, adjusted-HR 0.17, 95%CI 0.02-1.30, P = 0.088). Obesity, absence of diabetes mellitus, type II histology, and recurrent disease were the factors associated with decreased VTE risk with statin use (all, P-interaction<0.05).

conclusionOur study suggests that statin use may be associated with decreased risk of VTE in women with endometrial cancer.

Indexed as

AspirinEndometrial NeoplasmsFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIncidenceRetrospective StudiesVenous ThromboembolismAspirinHydroxymethylglutaryl-CoA Reductase InhibitorsAspirinEndometrial neoplasmsHydroxymethylglutaryl-CoA reductase InhibitorsIncidenceVenous thromboembolism

Identifiers

PMID30616901
PMCPMC7526861
OpenAlexW2907911263

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.